Initial Therapy: When Progression Occurs

Four phase 3 trials at ESMO 2026 brought news for people with small cell, EGFR, MET and KRAS G12C lung cancer, plus a caution about spacing out immunotherapy doses.

Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.

Adding Imdelltra to Imfinzi maintenance helped people with extensive-stage small cell lung cancer live a median of 21.1 months vs. 12.7 months with Imfinzi alone in the phase 3 DeLLphi-305 trial.

New results for lung and pancreatic cancer show newer targeted drugs may help some patients live longer. Here is what patients and caregivers should know.

Medicare will move ostomy supplies to eight national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.

An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.

The National Comprehensive Cancer Network released its first patient guideline written for caregivers on Oct. 27, 2026. The free guide covers emotional support, money, legal questions, medical tasks and caregivers' own well-being.

Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.